This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership.
The breast journal · 2020 · senior author
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2019 · senior author
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
The oncologist · 2019
Latest funding
- $852,300
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
CIHR · 2018 · Principal investigator
- $998,807
Palliative Care, Early & Systematic (PaCES): Impact on Patient & Health System Outcomes
CIHR · 2017 · Principal investigator
- $498,999
Mentorship Program in Innovative Integrative Oncology Clinical Trials: Moving from Best Evidence to Best Practice
CIHR · 2016 · Co-investigator
20 publications.
Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership.
Nixon NA, Simmons C, Lemieux J, Verma S
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer.
Savard MF, Khan O, Hunt KK, Verma S
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS
Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Merino Lara T, Helou J, Poon I, Sahgal A, Chung HT, Chu W, Soliman H, Ung Y, Verma S, Cheema P, Cheng S, Khanna S, Erler D, Zhang L, Cheung P
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
Matutino A, Amaro C, Verma S
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M
Prospective Evaluation of the Impact of the 21‐Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node‐Positive Breast Cancer in Ontario, Canada
Torres S, Trudeau M, Gandhi S, Warner E, Verma S, Pritchard KI, Petrella T, Hew‐Shue M, Chao C, Eisen A
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
Principal investigators: Morris, Donald G; Verma, Sunil
Keywords: Epigenetics; Mgmt; Olaparib; Parp Inhibition; Targeted Treatment; Temozolomide; Triple Negative Breast Cancer
Palliative Care, Early & Systematic (PaCES): Impact on Patient & Health System Outcomes
Principal investigators: Simon, Jessica E; Braun, Ted C; Kurien, Elizabeth; Verma, Sunil; Hagen, Neil A; Kerba, Marc; Sinnarajah, Aynharan
Keywords: End-Of-Life Care; Health Resource Utilization; Integrated Cancer And Palliative Care; Interrupted Time Series With Comparison Group; Patient-Centred Outcomes; Systematic Palliative Care
Mentorship Program in Innovative Integrative Oncology Clinical Trials: Moving from Best Evidence to Best Practice
Principal investigators: Carlson, Linda E
Keywords: Complementary Therapies; Fatigue; Meditation; Mind-Body Therapies; Online Interventions; Program Dissemination; Psychosocial Interventions; Psychosocial Oncology; Randomized Controlled Trials; Yoga
Palliative Care, Early & Systematic (PaCES): Impact on Patient & Health System Outcomes
Principal investigators: Simon, Jessica E; Braun, Ted C; Kurien, Elizabeth; Verma, Sunil; Hagen, Neil A; Kerba, Marc; Sinnarajah, Aynharan
Keywords: Health Resource Utilization; Interrupted Time Series With Comparison Group; Patient-Centred Outcomes; Systematic Palliative Care
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Oncology
- Medicine
- Physics
- Department of Medicine
- Department of Medical Biophysics
- Other
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Maureen Trudeau
Physics
1 shared papers, latest 2018
Arjun Sahgal
Faculty
1 shared papers, latest 2018
Paul Wheatley-Price
Department of Medicine
1 shared papers, latest 2018
Andrea Eisen
Oncology
1 shared papers, latest 2018
Andrea Eisen
Faculty
1 shared papers, latest 2018
Kelvin Chan
Medicine
1 shared papers, latest 2017
Robert Kerbel
Department of Medical Biophysics
1 shared papers, latest 2017
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.